{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:31:29Z","timestamp":1794864689924,"version":"4.9.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for hematological malignancies, yet its potential to drive lymphomagenesis poses significant clinical concerns. In this study, we investigated the mechanisms underlying CAR T-cell\u2013associated lymphomagenesis in the gastrointestinal (GI) tract on a single case, focusing specifically on the role of integrin \u03b14\u03b27 expression and a predisposing somatic SH2B3 mutation. We observed oligoclonal CAR T cells homing to, and clonally expanding in, the GI tract, with the dominant expanded clone harboring both a pathogenic SH2B3 mutation and a CAR transgene integration within a TFCP2 locus. The clonal CAR T cells subsequently transitioned beyond the GI tract into the peripheral blood, suggesting a potential pathway for systemic dissemination. We found clinical, histological, and molecular evidence demonstrating the efficacy of cyclosporine in reducing the expanded malignant clone and achieving durable clinical remission for more than a year. Our findings highlight the complex interplay between CAR T-cell therapy, preexisting genetic vulnerabilities, and the GI microenvironment, emphasizing the need for vigilant monitoring and tailored therapeutic strategies to address the risks associated with CAR T-cell lymphomagenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031423","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:23:18Z","timestamp":1764084198000},"page":"1191-1198","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-9666","authenticated-orcid":false,"given":"Hitomi","family":"Hosoya","sequence":"first","affiliation":[{"name":"1Division of Hematology and Cellular Therapy, Cedars-Sinai Medical Center, Los Angeles, CA"},{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando N.","family":"Bastidas Torres","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0428-0199","authenticated-orcid":false,"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-2883","authenticated-orcid":false,"given":"John","family":"Gubatan","sequence":"additional","affiliation":[{"name":"5Divison of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Najidh","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"},{"name":"6Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-3906","authenticated-orcid":false,"given":"George E.","family":"Duran","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Ehlinger","sequence":"additional","affiliation":[{"name":"7Center for Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2477-7888","authenticated-orcid":false,"given":"Claire","family":"Lohman","sequence":"additional","affiliation":[{"name":"7Center for Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles","family":"Wright","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"name":"7Center for Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal","family":"Mackall","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"},{"name":"7Center for Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA"},{"name":"8Parker Institute for Cancer Immunotherapy, Stanford University, Stanford, CA"},{"name":"9Division of Pediatric Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4651","authenticated-orcid":false,"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"},{"name":"10Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-7351","authenticated-orcid":false,"given":"Michael S.","family":"Khodadoust","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"},{"name":"11Department of Dermatology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2026031211215372300_bib1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026031211215372300_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2026031211215372300_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026031211215372300_bib4","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10297","key":"2026031211215372300_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2026031211215372300_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026031211215372300_bib7","unstructured":"U.S. Food and Drug Administration\n          . FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. Accessed 10 January 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics."},{"issue":"4","key":"2026031211215372300_bib8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"2026031211215372300_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"2026031211215372300_bib10","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"16","key":"2026031211215372300_bib11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2026031211215372300_bib12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","article-title":"Aggressive lymphoma after CD19 CAR T-cell therapy","volume":"391","author":"Kobbe","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2026031211215372300_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026031211215372300_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"2026031211215372300_bib15","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"2026031211215372300_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMc2504588","article-title":"Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T-cell therapy","volume":"393","author":"Aleman","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026031211215372300_bib17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"issue":"18","key":"2026031211215372300_bib18","doi-asserted-by":"crossref","first-page":"eabj1624","DOI":"10.1126\/sciadv.abj1624","article-title":"CancerVar: an artificial intelligence-empowered platform for clinical interpretation of somatic mutations in cancer","volume":"8","author":"Li","year":"2022","journal-title":"Sci Adv"},{"issue":"7","key":"2026031211215372300_bib19","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"2026031211215372300_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3324\/haematol.2020.274506","article-title":"Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma","volume":"107","author":"Bastidas Torres","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"2026031211215372300_bib21","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.exphem.2014.07.238","article-title":"A novel tumor suppressor sh2b3 in acute lymphoblastic leukemia","volume":"42","author":"Cheng","year":"2014","journal-title":"Exp Hematol"},{"issue":"suppl 1","key":"2026031211215372300_bib22","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2024-194488","article-title":"The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms [abstract]","volume":"144","author":"Montoro","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026031211215372300_bib23","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2024-204188","article-title":"Expanding the role of SH2B3: T cell large granular lymphocytosis (LGL) and common variable immune deficiency in the setting of biallelic SH2B3 mutations [abstract]","volume":"144","author":"Hangse","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026031211215372300_bib24","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"issue":"8","key":"2026031211215372300_bib25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2026031211215372300_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3324\/haematol.2020.274506","article-title":"Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma","volume":"107","author":"Bastidas Torres","year":"2022","journal-title":"Haematologica"},{"key":"2026031211215372300_bib27","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2026031211215372300_bib28","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma [abstract]","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"issue":"18","key":"2026031211215372300_bib29","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1073\/pnas.1000374107","article-title":"Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma","volume":"107","author":"Yoo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026031211215372300_bib30","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1158\/0008-5472.CAN-19-2908","article-title":"A feedback loop comprising EGF\/TGF\u03b1 sustains TFCP2-mediated breast cancer progression","volume":"80","author":"Zhao","year":"2020","journal-title":"Cancer Res"},{"issue":"9","key":"2026031211215372300_bib31","first-page":"6024","article-title":"LSF expression and its prognostic implication in colorectal cancer","volume":"7","author":"Jiang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"2026031211215372300_bib32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/10668969231189172","article-title":"Rhabdomyosarcoma with FUS::TFCP2 fusion in the mandible: a rare aggressive subtype, but can be misdiagnosed as ossifying fibroma","volume":"32","author":"Zhong","year":"2024","journal-title":"Int J Surg Pathol"},{"issue":"5","key":"2026031211215372300_bib33","doi-asserted-by":"crossref","first-page":"a006209","DOI":"10.1101\/mcs.a006209","article-title":"EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas","volume":"8","author":"Panferova","year":"2022","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"9","key":"2026031211215372300_bib34","doi-asserted-by":"crossref","first-page":"e23259","DOI":"10.1002\/gcc.23259","article-title":"Diagnostic and therapeutic implications of a FUS::TFCP2 fusion and ALK activation in a metastatic rhabdomyosarcoma","volume":"63","author":"Csizmok","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2026031211215372300_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/11\/1191\/2508930\/blood_bld-2025-031423-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/11\/1191\/2508930\/blood_bld-2025-031423-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:22:05Z","timestamp":1773328925000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/11\/1191\/548426\/Long-term-follow-up-of-gastrointestinal-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031423","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,12]]},"published":{"date-parts":[[2026,3,12]]}}}